NeoVid Pharmaceuticals Announces Investigation of New Cancer Drug

Share Article

A new cancer drug compound (dTCTinicyclic acid HCL), given the brand name Azatrol, is being investigated for a cure to cancer.

Today, Neovid Pharmaceuticals LLC (neovid.com) announced the introduction of an investigational new cancer drug, Azatrol™ (dTCTinicylic acid HCL). The company emphasizes that this drug is in the most early stages of investigation requiring extensive basic research in order to prove its theory.

This endeavor is comprised of the biosynthesis of several compounds resulting in the creation of dTCtinicylic acid HCL (which has been given the brand name Azatrol™ by NeoVid). As conceived, dTCtinicylic acid HCL will be injected into a tumor site and then It is hypothesized that malignant cells will cease to multiply, ultimately detaching from the host and subsequently becoming absorbed into the blood stream. The destroyed cells will then be safely eliminated through the patient’s own immune system.

According to John T. Jeter, President and CEO of Neovid, the company is in the process of seeking adequate funding sources to proceed with the basic research. He further reports that the fundamental science behind the investigational new compound is founded upon naturally occurring substances commonly found in phytopharmaceuticals. By subjecting these compounds to a proprietary heat process, a new molecule (dTCTinicyclic acid HCL) may be formulated.

Mr. Jeter goes on to point out that this proposed compound is highly speculative at this point and requires further investigation. To quote Mr Jeter, “The research on our investigational compound is exciting because it is a synthesis of natural plant substances. This is not as far reaching as one may think considering the fact that a powerful cancer drug Taxol® is formulated originally from the Pacific Yew Tree or Paclitaxel and another cancer drug is based the chemical navelbine found in missile-toe.”

For more information, please contact the company at http://neovid.com, by phone: 610-692-3215 or by e-mail.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

John Jeter
Visit website